Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine
Purpose: Current acute migraine treatment consists of migraine-specific agents, namely triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs and acetaminophen (paracetamol). Both have tolerability issues, or are not indicated, or both, in many patients; they may...
Main Authors: | David Moreno-Ajona, Abigail Pérez-Rodríguez, Peter J. Goadsby |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Medicine in Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098620300403 |
Similar Items
-
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
by: Matilde Capi, et al.
Published: (2021-04-01) -
Blocking CGRP in migraine patients – a review of pros and cons
by: Marie Deen, et al.
Published: (2017-09-01) -
The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse
by: Willem Sebastiaan van Hoogstraten, et al.
Published: (2019-05-01) -
New strategies for migraine treatment and prevention
by: Waldemar Brola, et al.
Published: (2019-10-01) -
Gepants for abortive treatment of migraine: A network meta‐analysis
by: Peiwei Hong, et al.
Published: (2020-08-01)